IP Library Granted Patent US 11,109,801
Granted Patent B2
US 11,109,801 · App. 16/578,298 · Granted Sep 7, 2021

Method of measuring efficacy of treatment for an autoimmune disease in vivarium animals

Inventors: Laura Schaevitz (Los Gatos, CA); Daniel J. Ford (Belmont, CA)
Assignee: Recursion Pharmaceuticals, Inc.
A61B5/4848A01K1/031A01K29/005A61B5/1118A61B5/4076A61B5/4842A61B5/7282A61B5/7257A61B2503/40A61B2503/42A61D99/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,109,801
App. No.
16/578,298
Granted
Sep 7, 2021
Kind
B2
Abstract

A method of measuring efficacy of test treatment of an autoimmune disease in an animal in a vivarium is described. Animal activity data is collected at multiple times during the night. Sequential time regions of the night are identified as high-activity, activity-drop, or low-activity regions. Embodiments are described to quantify a drop, during the night, of an animal's activity level. These quantified activity-drop scalars for consecutive nights are accumulated in an animal health dataset. This dataset is compared to healthy animals, a standard of care or a reference treatment for the first disease to determine efficacy of the test treatment. One embodiment quantifies an activity-drop by fitting straight-line curves through the data in the three nightly regions. Other embodiment uses a Fourier transform on a circle, LASSO, RANSAC or regression analyses for curve fitting. Another embodiment compares areas under data curves in the regions. Animals may be housed in cages with other animals.

Claims (21)

1. A method of measuring efficacy of a first treatment of an autoimmune disease in a study animal in a vivarium comprising the steps of:

(a) placing the study animal in a cage free of electronic penetrations in the vivarium and enrolling the study animal in a study;

(b) electronically observing one or more animal activities in real-time of the study animal using a combination of electronic cameras, infrared (IR) lighting of the study animals, and electronic hardware including computation and communication hardware;

(c) selecting a single “activity-drop metric” from the set: {regression analysis, LASSO, RANSAC, Monte Carlo} with an associated scalar “activity-drop value”;

(d) collecting a set of “nightly activity data” comprising values of the associated scalar activity drop value from electronically observing the study animal repeatedly and continually for a night;

(e) identifying automatically three consecutive time regions in the nightly activity data: a “high-activity region,” an “activity-drop region,” and a “low-activity region;”

(f) applying the activity-drop metric to the three consecutive regions, generating a nightly activity-drop value;

(g) adding the nightly activity-drop value into an “animal health dataset,” wherein the animal health dataset comprises the resulting nightly activity-drop values;

(h) iterating steps (b) through (g) for sequential nights until a terminating condition is reached;

wherein the study animal is housed in a home cage in the vivarium; and

wherein the collected data comprises the animal health dataset.

wherein the efficacy of the first treatment is a comparison of the animal health dataset to a reference treatment for the autoimmune disease;

(i) removing the study animal from the study when the terminating condition is reached.

2. The method of claim 1 further comprising:

(j) repeating steps (b) through (h) with multiple study animals in a first cohort;

(k) computing an average of the nightly activity-drop values, from step (f), for each night, for each of the multiple animals in the first cohort; wherein the each night is time shifted for each of the multiple animals in the cohort to align to an each reference night of each animal;

(l) adding the average of each night from step (k) into a cohort health dataset;

wherein the efficacy of the first treatment further includes comparison of the cohort health dataset to the reference treatment for the autoimmune disease.

3. The method of claim 2 wherein:

at least some of the multiple animals in the first cohort are housed in home cages in the vivarium wherein the home cages contain more than one animal; and

wherein the collecting step (d) of the animals is performed on animals in their home cage.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE APPLICATION NUMBER PREVIOUSLY RECORDED AT REEL: 053047 FRAME: 0191. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 4, 2021
From: VIUM, INC.
To: SILICON VALLEY BANK
Reel/Frame 057085/0787 →
CORRECTIVE ASSIGNMENT TO CORRECT THE D877354 PREVIOUSLY RECORDED AT REEL: 055620 FRAME: 0040. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SERCURITY INTEREST. Recorded Aug 4, 2021
From: SILICON VALLEY BANK
To: RECURSION PHARMACEUTICALS, INC.
Reel/Frame 057086/0684 →
RELEASE OF SECURITY INTEREST Recorded Mar 16, 2021
From: SILICON VALLEY BANK
To: RECURSION PHARMACEUTICALS, INC.
Reel/Frame 055620/0040 →
SECURITY INTEREST Recorded Jun 25, 2020
From: VIUM, INC.
To: SILICON VALLEY BANK
Reel/Frame 053047/0192 →
Continuity (2)
Continuation 15282364 · Sep 30, 2016
Related Publication 20200015741A1 · Jan 16, 2020